September 18, 2026, (Inside AI) — Anthropic has established a physical biology laboratory in the San Francisco Bay Area, confirming a significant expansion of its artificial intelligence ambitions into experimental drug science. The move, disclosed by two people familiar with the matter, places the AI safety-focused startup in direct operational territory long dominated by traditional biotechnology firms.
The company's head of life sciences, Eric Kauderer-Abrams, confirmed the wet lab's existence in an interview, stating that computational biology alone is insufficient for the company's goals.
"We believe that to do biology, the final test is still and will be for a while in real lab work," Kauderer-Abrams said. "We absolutely are doing that today, and I would describe our approach as being typical of what you would see in most biotech companies, where there's some amount of that that we're doing in our own facilities and some amount of that that we're working with external partners on."
A spokesperson later clarified that the facility is not intended for drug discovery specifically, though the company declined to elaborate on its precise function. This distinction suggests the lab may focus on validating AI-generated hypotheses or automating robotic workflows rather than pursuing a specific therapeutic candidate.
Balancing Existential Risk With Clinical Ambition
The laboratory's establishment occurs during a period of intense internal contradiction for Anthropic. In the past two weeks, company researchers have publicly warned that advanced AI could lead to human extinction, and the company reported finding examples where its systems could have been misused for biological weapons development. CEO Dario Amodei has simultaneously called for a development slowdown, citing catastrophic risks.
Yet the company is preparing for a potentially $2 trillion initial public offering to fund further AI development. This tension between safety advocacy and commercial expansion defines the current strategy.
"In our life-science work, we're always balancing these things," Kauderer-Abrams said, "making models better in ways that we think will uplift and accelerate developing medicines, and being thoughtful and careful about how we deploy it to limit the risk."
The personal motivation for Amodei is documented. In a recent essay, he revealed that a disease killed his father only a few years before a cure became available. Kauderer-Abrams echoed this mission-driven approach.
"The mission of the company is to develop powerful AI in such a way that benefits the world," he said. "By far, we see the biggest opportunity for that in the life sciences, and that is motivating everything that we're doing."
Anthropic's strategy involves pushing its Claude AI to direct robotic units for experiments with limited human intervention. The company launched the Model Hardware Standard in August to help AI operate laboratory equipment. However, a spokesperson emphasized that human oversight remains essential for safety.
"We're in the very early innings of using AI to automate the execution of lab work," Kauderer-Abrams said, "an area that has the potential to bring about meaningful acceleration in so many different processes."
The company has signaled its drug program intentions since a San Francisco event in June. It launched software called Claude Science, added Novartis CEO Vas Narasimhan to its board, and acquired startup Coefficient Bio for approximately $400 million in stock. Anthropic confirmed the acquisition but declined to comment on the price.
Recent job postings reveal the scope of expansion. One listing sought a leader to ramp up procurement operations. Another solicited an expert on "protein and nucleic acid characterization." A third stated: "Our goal is to speed up progress in the life sciences by an order of magnitude."
Kauderer-Abrams indicated that life sciences already represents one of Anthropic's largest investment areas by headcount and resources. The company's focus includes targeting conditions previously considered "undruggable," such as those requiring bispecific and trispecific antibodies, complex molecules that can hit multiple targets simultaneously.
Anthropic faces a trust challenge. Pharmaceutical customers may worry that the AI startup could learn from their competing drug programs, even as Anthropic walls off their data. The company provides AI services to major pharmaceutical companies including Roche's Genentech, Bristol Myers Squibb, and Novo Nordisk.
"We're not competing with pharma and biotech companies that make their business in bringing drugs to market," Kauderer-Abrams said, noting that Anthropic has set a boundary against running clinical trials for now.
The precise diseases Anthropic is addressing and its progress remain unclear. Once a molecule is identified, bringing a drug to market can take years of human trials, a challenge Anthropic has not yet taken on. Rival Alphabet's drug discovery arm, Isomorphic Labs, has worked for years to reach the clinic and earlier delayed that goal to the end of 2026. The path from wet lab to approved therapy remains long and uncertain, with most drugs failing clinical safety and efficacy trials. Anthropic's laboratory represents a small step toward an enormous ambition, one that will be measured not by computational benchmarks but by physical results in the years ahead.
